{
  "extraction_date": "2025-12-23",
  "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
  "phase": "4",
  "priority": "Phase 4 - Emerging Indications Expansion",
  "total_studies": 12,
  "studies": [
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_001",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Survey of cannabis use in patients with amyotrophic lateral sclerosis",
      "citation": "Amtmann et al. 2004. The American Journal of Hospice and Palliative Care 21: 95-104.",
      "publication_year": 2004,
      "journal": "The American Journal of Hospice and Palliative Care",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_002",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid",
      "citation": "Raman et al. 2004. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.",
      "publication_year": 2004,
      "journal": "Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_003",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset",
      "citation": "Shoemaker et al. 2007. Journal of Neurochemistry 101: 87.",
      "publication_year": 2007,
      "journal": "Journal of Neurochemistry",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_004",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of Sativex-like combination of phytocannabinoids: Interest for future therapies in amyotrophic lateral sclerosis",
      "citation": "Moreno-Martet et al. 2014. CNS Neuroscience and Therapeutics 20: 809-815.",
      "publication_year": 2014,
      "journal": "CNS Neuroscience and Therapeutics",
      "intervention": {
        "cannabis_type": "Sativex-like phytocannabinoid combination",
        "cannabinoid_profile": "balanced THC:CBD",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_005",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Emerging potential of cannabidiol in reversing proteinpathies",
      "citation": "Dash et al. 2021. Ageing Research Reviews 65.",
      "publication_year": 2021,
      "journal": "Ageing Research Reviews",
      "intervention": {
        "cannabis_type": "Cannabidiol",
        "cannabinoid_profile": "CBD-dominant",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_006",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "A systematic review of the effectiveness of medical cannabis for psychiatric, movement, and neurodegenerative disorders",
      "citation": "Lim et al. 2017. Clinical Psychopharmacology and Neuroscience 30: 301-312.",
      "publication_year": 2017,
      "journal": "Clinical Psychopharmacology and Neuroscience",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_RCT_001",
      "study_type": "RCT",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial",
      "citation": "Weber et al. 2009. Journal of Neurology, Neurosurgery, and Psychiatry 81: 1135-1140.",
      "publication_year": 2009,
      "journal": "Journal of Neurology, Neurosurgery, and Psychiatry",
      "intervention": {
        "cannabis_type": "Synthetic THC",
        "cannabinoid_profile": "THC-dominant",
        "delivery_method": "oral",
        "dosing_information": "5 mg twice daily (per NORML summary)",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": 22,
        "institution": "",
        "country": "",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_007",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Study protocol for a randomized, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based medicine extract in slowing the disease progression of amyotrophic lateral sclerosis or motor neurone disease: The EMRALD trial",
      "citation": "Urbi et al. 2019. BMJ Open 11.",
      "publication_year": 2019,
      "journal": "BMJ Open",
      "intervention": {
        "cannabis_type": "Cannabis-based medicine extract",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": true,
        "placebo_controlled": true
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_008",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials",
      "citation": "Carter et al. 2010. American Journal of Hospice & Palliative Medicine 27: 347-356.",
      "publication_year": 2010,
      "journal": "American Journal of Hospice & Palliative Medicine",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "AMYOTROPHIC_LATERAL_SCLEROSIS_OBSERVATIONAL_009",
      "study_type": "observational",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?",
      "citation": "Giacoppo and Mazzon. 2016. Neural Regeneration Research 11: 1896-1899.",
      "publication_year": 2016,
      "journal": "Neural Regeneration Research",
      "intervention": {
        "cannabis_type": "",
        "cannabinoid_profile": "",
        "delivery_method": "",
        "dosing_information": "",
        "treatment_duration": ""
      },
      "outcomes": {
        "key_findings": [],
        "outcome_measures": [],
        "quantitative_results": [],
        "adverse_effects": [],
        "effect_size_category": "unknown"
      },
      "study_quality": {
        "sample_size": null,
        "institution": "",
        "country": "",
        "randomized": false,
        "placebo_controlled": false
      },
      "notes": "Extracted from NORML ALS research library (references section)."
    },
    {
      "study_id": "CT_NCT01776970",
      "study_type": "RCT",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease",
      "citation": "ClinicalTrials.gov NCTNCT01776970",
      "publication_year": 2015,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis Sativa extract Oromucosal spray",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "modified 5 - points modified Ashworth scale (AS)."
        ],
        "outcome_measures": [
          "modified 5 - points modified Ashworth scale (AS)."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01776970",
        "enrollment": 60,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01776970"
      }
    },
    {
      "study_id": "CT_NCT00812851",
      "study_type": "RCT",
      "condition": "AMYOTROPHIC_LATERAL_SCLEROSIS",
      "study_title": "Randomized Placebo-Controlled Crossover Trial With THC (Delta 9-Tetrahydrocannabinol) for the Treatment of Cramps in Amyotrophic Lateral Sclerosis (ALS)",
      "citation": "ClinicalTrials.gov NCTNCT00812851",
      "publication_year": 2008,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase NA",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "severity of cramps"
        ],
        "outcome_measures": [
          "severity of cramps"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00812851",
        "enrollment": 24,
        "phase": "NA",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00812851"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 0,
    "pubmed_added": 0,
    "total_added": 0,
    "expansion_date": "2025-12-23T23:40:06.115515"
  }
}